[1]
2024. Bimekizumab 3-year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3/3b Trials. SKIN The Journal of Cutaneous Medicine. 8, 1 (Jan. 2024), s304. DOI:https://doi.org/10.25251/skin.8.supp.304.